ROG Stock Overview
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 5/6 |
Roche Holding AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF 261.60 |
52 Week High | CHF 288.20 |
52 Week Low | CHF 212.90 |
Beta | 0.15 |
11 Month Change | -3.58% |
3 Month Change | -7.00% |
1 Year Change | 10.45% |
33 Year Change | -29.04% |
5 Year Change | -13.62% |
Change since IPO | 902.30% |
Recent News & Updates
Recent updates
These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well
Sep 10We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt
Apr 17Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year
Mar 06Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 09Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear
Feb 08Market Cool On Roche Holding AG's (VTX:ROG) Earnings
Dec 29We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt
Dec 07Shareholder Returns
ROG | CH Pharmaceuticals | CH Market | |
---|---|---|---|
7D | -1.6% | -0.9% | -1.2% |
1Y | 10.4% | 11.8% | 7.0% |
Return vs Industry: ROG underperformed the Swiss Pharmaceuticals industry which returned 11.8% over the past year.
Return vs Market: ROG exceeded the Swiss Market which returned 7% over the past year.
Price Volatility
ROG volatility | |
---|---|
ROG Average Weekly Movement | 2.2% |
Pharmaceuticals Industry Average Movement | 3.0% |
Market Average Movement | 3.3% |
10% most volatile stocks in CH Market | 7.3% |
10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: ROG has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: ROG's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1896 | 103,605 | Thomas Schinecker | www.roche.com |
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas.
Roche Holding AG Fundamentals Summary
ROG fundamental statistics | |
---|---|
Market cap | CHF 211.93b |
Earnings (TTM) | CHF 10.62b |
Revenue (TTM) | CHF 60.58b |
19.6x
P/E Ratio3.4x
P/S RatioIs ROG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ROG income statement (TTM) | |
---|---|
Revenue | CHF 60.58b |
Cost of Revenue | CHF 15.43b |
Gross Profit | CHF 45.16b |
Other Expenses | CHF 34.54b |
Earnings | CHF 10.62b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 13.33 |
Gross Margin | 74.54% |
Net Profit Margin | 17.53% |
Debt/Equity Ratio | 104.8% |
How did ROG perform over the long term?
See historical performance and comparison